Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Total Liabilities (2019 - 2025)

Immunocore Holdings' Total Liabilities history spans 4 years, with the latest figure at -$381.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 158.73% year-over-year to -$381.0 million; the TTM value through Dec 2025 reached -$381.0 million, down 158.73%, while the annual FY2025 figure was -$381.0 million, 158.73% down from the prior year.
  • Total Liabilities for Q4 2025 was -$381.0 million at Immunocore Holdings, down from $705.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $706.8 million in Q3 2024 and bottomed at -$381.0 million in Q4 2025.
  • The 4-year median for Total Liabilities is $634.5 million (2024), against an average of $283.8 million.
  • The largest annual shift saw Total Liabilities soared 298.56% in 2024 before it tumbled 158.73% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $187.9 million in 2022, then rose by 21.45% to $228.2 million in 2023, then soared by 184.36% to $648.8 million in 2024, then crashed by 158.73% to -$381.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Total Liabilities are -$381.0 million (Q4 2025), $705.9 million (Q3 2025), and $693.9 million (Q2 2025).